Ocular manifestations and biomarkers of Gulf War Illness in US veterans

Brandon S. Baksh1,2, Kristen L. Zayan1,2, Raquel Goldhardt1,3, Elizabeth R. Felix4,5, Nancy Klimas4,6 & Anat Galor1,3*

Gulf War Illness (GWI) is a multisystem disease with variable presentations, making diagnosis difficult. Non-invasive biomarkers would aid in disease diagnosis. We hypothesized that the eye could serve as a biomarker for GWI. We performed a retrospective case–control study using a sample of 1246 patients seen during a 5-month period in an optometry clinic. We identified veterans who were active duty during the Gulf War Era and either had a questionnaire-based diagnosis of GWI (cases) or did not (controls). Medical records were reviewed for eye and medical co-morbidities, medication use, and retinal macular and nerve fiber layer (NFL) thicknesses based on optical coherence tomography (OCT) images. Compared to controls (n = 85), individuals with GWI (n = 60) had a higher frequency of dry eye symptoms (50% vs 32.9%, p = 0.039). Multivariable analysis revealed average retinal NFL thickness (odds ratio; OR = 0.95), cup-to-disc ratio (OR = 0.005), age (OR = 0.82), and PTSD (OR = 20.5) were predictors of a GWI diagnosis. We conclude that GWI is associated with dry eye symptoms and RNFL thinning may serve as a biomarker for disease.

On return from the 1990 to 1991 Gulf War, about 200,000 veterans reported a wide range of symptoms that have been categorized as Gulf War Illness (GWI)1. GWI covers a wide range of symptoms including (1) fatigue (2) mood and cognition disorders and (3) musculoskeletal disorders. The pathophysiology of GWI is believed to involve central nervous system (CNS) dysfunction manifesting in multiple systems. Studies have examined CNS abnormalities in GWI. In a study of 96 veterans with GWI, functional magnetic resonance imaging (fMRI) showed significant decreases in the pre-frontal cortex and white-matter activity during high-demand working memory tasks compared to 44 matched controls.3 These neurological changes have been linked to chemical exposure while in theater, including pesticides. A study of 7,971 United Kingdom Gulf War veterans (GWV) with GWI symptoms revealed a positive correlation between neurological symptoms and days handling pesticides, r = 0.08, p < 0.001. These data suggest GWI involves nervous system alterations in response to chemical exposures that have widespread biological effects.

Several age-related diseases have been found to be more common in GWI veterans compared to Gulf War Era (GWE) veterans not deployed to the Gulf War. These diseases include hypertension, coronary heart disease, and chronic obstructive pulmonary disease.4 There is a paucity of data, however, on the frequency of age-related eye diseases in GWI, even though there is an increased frequency of blurry vision and photophobia in GWV compared to non-GWV1. Thus veterans with GWI may be at increased risk for age-related eye disease and this association should be explored. Furthermore, GWI may specifically be at risk for dry eye (DE) given the overlap in symptom profile between GWI, fibromyalgia, and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), the latter two of which have been associated with DE symptoms5, 6. Given these data, we hypothesized that individuals with GWI have a higher frequency of age-related eye diseases, including DE symptoms, compared to GWE veterans that do not meet GWI diagnostic criteria.

Beyond the frequency of overt disease, there is a need to identify sub-clinical biomarkers of GWI as diagnosis is difficult given varied presentations. A potential modality to identify sub-clinical disease is OCT, which has been employed to diagnose and monitor disease progression in Multiple Sclerosis (MS), Parkinson’s disease (PD), and Alzheimer’s disease (AD)7–10. For example, OCT parameters, such as retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL) thickness correlated with changes in clinical status11, 12, visual acuity, and disability in...
Based on findings in other neurodegenerative diseases, we hypothesized that individuals with GWI, but without overt retinal and optic nerve pathology, would have differences in OCT measures compared to GWE veterans without a GWI diagnosis. To evaluate this hypothesis, we performed a retrospective case–control study.

**Materials and methods**

**Study population and Gulf War Illness diagnosis.** The study population consisted of 1246 patients who were seen between November 18, 2018, and April 18, 2019, in the optometry clinic at the Miami Veterans Affairs Hospital (VA). Individuals were split into two groups: those with a diagnosis of GWI and those who served during the GWE who did not meet the criteria for GWI (controls) (Fig. 1). To identify all potential GWE veterans, we contacted 536 individuals seen in the optometry clinic during the relevant date range with a birthday between January 1, 1960, and December 31, 1972. Patients were diagnosed with GWI if they were
deployed to the Gulf War and met the Kansas criteria via clinic or phone interview. The Kansas criteria requires: symptoms started during or after deployment and were present in the year prior to assessment, and one severe or two moderate symptoms in at least three of six domains, including (1) fatigue, (2) pain, (3) neurologic and mood, (4) gastrointestinal, (5) respiratory, and (6) skin. Veterans were included in the control group if they were active duty and deployed to the Gulf War, but did not meet Kansas criteria, or were active duty, but not deployed to the Gulf War.

Individuals with GWI were further sub-typed based on reported symptoms. Specific symptom clusters have been found to be useful when grouping GWI veterans. In our study, we identified individuals with “severely impaired cognition” syndrome if they had at least 5 out of 6 of the following symptoms: problems with memory, feelings of irritability/angry outbursts, headaches, depression, difficulty concentrating, and trouble finding words when speaking.

The study was first approved by the Miami VA Institutional Review Board (IRB) as a quality assurance study. Approval was then obtained to link the questionnaire to clinical records. Informed consent was waived by the Miami VA IRB. The study was conducted in accordance with the principles of the Declaration of Helsinki and complied with the requirements of the United States Health Insurance Portability and Accountability Act.

Data collected. Patient charts were retrospectively reviewed for demographics, co-morbidities, medications, and diagnoses of eye diseases including glaucoma, age-related macular degeneration, diabetic retinopathy, and DE symptoms or signs. DE symptoms were considered present if terms such as ‘dryness’, ‘irritation’, or “foreign body sensation” were listed as complaints in the clinical records. DE signs were considered present if any of the criteria were documented: fast tear break-up time (TBUT), positive fluorescein corneal staining, low tear lake, or Schirmer’s test < 5 mm wetting at 5 min.

Imaging. Of 145 veterans identified via phone survey or medical record review as having served during the GWE, 94 individuals underwent OCT imaging (RNFL, GCL-inner plexiform layer (IPL), and macular maps) during their next routine clinic visit using a Cirrus HD-OCT (Carl Zeiss Meditec Inc, Dublin, California, USA). Of note, the 94 individuals with imaging were slightly older than the 51 who did not have OCT imaging available (51 ± 4.1 vs 52 ± 4.2, p = 0.013) but the remaining demographics were similar between the groups. OCT data from 28 individuals were subsequently excluded from the final analysis given overt retinal or optic nerve disease, including glaucoma, ocular hypertension retinopathy, retinal hemorrhage, diabetic retinopathy, or dry age-related macular degeneration (ARMD). Thus, 66 individuals with no diagnosis of retinal or optic nerve pathology and were included in the imaging analysis. Of note, 2 of 28 individuals with GWI and 2 of 38 controls did not have all 3 OCT maps (RNFL, GCL-IPL, macula). RNFL images were available for 27 GWI and 36 controls, GCL for 26 GWI and 37 controls, and macula for 27 GWI and 38 controls. For all analyses, the thinner RNFL, GCL, and macular value from either eye was used.

Data analysis. Statistical analyses were performed using SPSS 24.0 (IBM Corp, Armonk, NY) statistical package. Descriptive statistics were used to summarize patient demographic and clinical information. Normality of the data was assessed using the Kolmogorov–Smirnov test. Differences in continuous variables between two groups were analyzed using the Student's t-test or Mann–Whitney U test, as appropriate. Differences in continuous variables between more than two groups were analyzed using the Kruskal–Wallis H test. Differences in categorical data were compared using Chi-square or Fisher’s exact test, as appropriate. Predictors of GWI were analyzed using forward stepwise binary logistic regression. All reported p-values are two-tailed and p < 0.05 was considered statistically significant. In this paper, we opted to give information on all variables being compared as opposed to correcting the p-value (e.g. Bonferroni) since the latter methodology has its own limitations.

Results

Study population. During the above timeframe, 1246 veterans were seen in the optometry clinic. Of those, 145 served during the GWE, 60 met the criteria for GWI, and 85 served as controls. Twenty-eight GWI veterans were identified as having “severely impaired cognition.” Demographics were comparable between GWI veterans and controls (Table 1). Veterans with GWI had significantly higher frequencies of post-traumatic stress disorder (PTSD) (45% vs 20%, p = 0.001), chronic fatigue syndrome (13% vs 1%, p = 0.004), and fibromyalgia (18% vs 2%, p = 0.001) compared to controls. Of note, non-steroidal anti-inflammatory drug (NSAID) and naltrexone use were significantly more common in GWI vs controls (60% vs 42%, p = 0.036 and 15% vs. 0%, p < 0.001, respectively).

Frequency of eye diseases in the populations. Overall, individuals with GWI had a similar frequency of any eye disease, 73% vs 61%, p = 0.13. DE symptoms were significantly more common in GWI compared to controls, 50% vs 33%, p = 0.04. The GWI group tended to have higher frequencies of diabetic retinopathy (7% vs 4%, p = 0.45), and dry ARM (3% vs 0%, p = 0.17), compared to controls, but the results were not significant with low frequencies in both groups. Compared to controls, GWI veterans with “severely impaired cognition” had significantly higher frequencies of both DE symptoms (61% vs 33%, p = 0.009) and signs (39% vs 19%, p = 0.028).

Optical coherence tomography as a potential biomarker of Gulf War Illness. Of the 94 individuals with available OCT images, 66 veterans (28 GWI and 38 controls) had no known optic nerve or retinal disease. Although not significant, almost all mean RNFL measurements were thinner in GWI compared to controls, with the largest difference seen in the inferior RNFL (109.33 μm ± 26.20 vs 117.00 μm ± 24.29,
p = 0.13, a 6.6% decrease) (Supplementary Table S1 and Fig. 2). Similarly, all mean macular OCT measurements were thinner in veterans with GWI vs controls, with the largest decrease in the superior outer segment of the macula (271.00 μm ± 14.03 vs 277.45 μm ± 14.20, p = 0.12, a 2.32% decrease). Interestingly, almost all mean GCL parameters were thicker in the GWI group, with the largest increase in the inferotemporal GCL segment (78.65 μm ± 9.03 vs 77.29 μm ± 11.03, p = 0.245, a 1.75% increase). All other OCT measurements for GWI and controls are shown in Supplementary Table S1.

Further sub-grouping the population by severity of cognitive deficit, OCT data were available for 20 GWI veterans with “severely impaired cognition,” 7 GWI veterans without “severely impaired cognition,” and 38 controls. Of note, one individual with GWI was not included in this sub-analysis as questionnaire sub-score data was not available. Since OCT data for these groups were non-parametric, the Kruskal–Wallis H test was used to assess statistical differences between groups. GWI veterans with “severely impaired cognition” had significantly thinner inferior GCL (72.5 μm ± 12.0 vs 82.66 μm ± 2.74, p = 0.004, a 12% decrease) and inferotemporal GCL (76.8 μm ± 9.4 vs 85.0 μm ± 3.22, p = 0.011, a 9.7% decrease) compared to GWI veterans without the syndrome. The findings were similarly pronounced when GWI veterans with “severely impaired cognition” syndrome were compared to controls without GWI. Interestingly, GWI veterans without “severely impaired cognition” had significantly thicker values in inferior (82.67 μm ± 2.73 vs 76.24 μm ± 9.66, p = 0.015, a 8.42% increase) and inferotemporal GCL (85.00 μm ± 3.22 vs 77.30 μm ± 11.03, p = 0.006, a 9.97% increase) compared to controls without GWI.

**Predictors of Gulf War Illness.** To determine if specific demographics and OCT parameters could predict a diagnosis of GWI, we used all veterans with available OCT data to perform forward stepwise binary logistic regression with GWI (yes/no) as the dependent variable. Beyond OCT measures mentioned in the methods sec-

| Table 1. Demographic and comorbidities of the study population. Continuous variables are expressed as mean ± standard deviation (minimum–maximum). Categorical variables are expressed as percent (n). Mann–Whitney U test was used for all continuous variables. Pearson Chi Square was used for all categorical variables unless otherwise noted. GWI Gulf War Illness, Control Individuals who served in 1990–91 who do not meet criteria for GWI, ARMD age-related macular degeneration, SD standard deviation, n number in group, PTSD post-traumatic stress disorder. *Statistically significant difference at a p-value < 0.05 between GWI and control. **Symptoms or signs. Fisher’s Exact Test. |
|-----------------|-----------------|-----------------|
| **Demographics** | **GWI (n=60) | **Control (n=85) | **P-value** |
| Age (years) | 52.1 ± 4.78 (45–71) | 52.7 ± 3.84 (46–60) | 0.39 |
| Male gender | 85% (51) | 82% (70) | 0.67 |
| White race | 41% (25) | 37% (32) | 0.81* |
| Hispanic ethnicity | 26% (16) | 20% (17) | 0.42 |
| **Non-ocular comorbidities** | | | |
| Diabetes | 33% (20) | 24% (21) | 0.26 |
| Hypertension | 43% (26) | 50% (43) | 0.39 |
| Hypercholesterolemia | 51% (31) | 49% (42) | 0.92* |
| PTSD | 45% (27) | 20% (17) | 0.001* |
| Depression | 38% (23) | 37% (32) | 0.93 |
| Arthritis | 20% (12) | 8% (7) | 0.039* |
| Sleep apnea | 56% (34) | 47% (40) | 0.25 |
| Chronic fatigue syndrome | 13% (8) | 1% (1) | 0.004** |
| Fibromyalgia | 18% (11) | 2% (2) | 0.001* |
| **Ocular comorbidities** | | | |
| Dry eye** | 50% (30) | 34% (29) | 0.06 |
| Symptoms | 50% (30) | 33% (28) | 0.039* |
| Signs | 23% (14) | 18% (16) | 0.51 |
| Ocular hypertension | 5% (3) | 10% (9) | 0.36* |
| Glaucoma | 15% (9) | 17% (15) | 0.67 |
| Cataract | 11% (7) | 7% (6) | 0.34 |
| Diabetic retinopathy | 7% (4) | 4% (3) | 0.45* |
| Dry ARM | 3% (2) | 0% (0) | 0.17* |
| Wet ARM | 0% (0) | 0% (0) | |
| Retinal hemorrhage | 1% (1) | 1% (1) | 1.00* |
| Vitreous degeneration | 3% (2) | 4% (4) | 1.00* |
| Keratoconus | 5% (3) | 2% (2) | 0.65* |
| Any eye disease | 73% (44) | 61% (52) | 0.13 |
In this study, we did not detect significant differences in the overall frequency of age-related eye diseases in individuals with GWI. However, dry eye symptoms were significantly more common in GWI compared to controls, which aligns with other diseases that have similar symptomology, such as fibromyalgia and chronic fatigue syndrome. There are many potential contributors to the noted association, including systemic inflammatory processes that lead to ocular surface inflammation and peripheral and/or central nerve abnormalities that lead to persistent symptoms of dryness.

Given the need for GWI biomarkers, we also compared retinal and optic nerve measures with OCT imaging. We found trends for macular OCT and RNFL thinning but GCL thickening in cases compared to controls. These differences became significant when GWI individuals with “severely impaired cognition” were compared to controls.
to both individuals with GWI but without “severely impaired cognition” and controls. These data highlight the heterogeneous nature of GWI and suggest that different disease processes likely drive the clinical heterogeneity. Diagnostics tests are thus needed to detect disease but also to sub-type based on underlying pathophysiological mechanisms.

Similar to GWI, RNFL thinning has also been described in individuals with PD as compared to controls, with the temporal and nasal regions most affected. In fact, the magnitude of inferior RNFL reduction in our GWI cohort (6.6%) is in the range of what has been reported in PD (6.2–15%). This becomes relevant as studies have found other similarities between GWI and PD. In an MRI study of 293 Gulf War veterans compared to healthy controls, individuals with GWI had significantly more PD-like symptoms and reduced basal ganglia volumes (a common radiological feature of PD) as compared to controls. Interestingly, the superior and temporal regions were most significantly affected in AD, as compared to the nasal and inferior regions in GWI. OCT findings have also been reported in MS, with overall mean reductions in RNFL thickness of 7.2% and temporal reductions of 23% as compared to controls. While the magnitude of overall RNFL reduction in GWI is smaller as compared to studies in PD, AD, and MS, these data highlight RNFL thinning as a marker of neurodegeneration with GWI showing similar trends.

Interestingly, in contrast to RNFL thinning, GCL values were thicker in GWI as compared to controls. This is the opposite of what has been described in other neurodegenerative diseases. We hypothesize that the discrepancy between GCL findings in GWI as compared to other neurodegenerative disorders are driven by competing mechanisms in GWI. While RNFL thinning can be an indicator of neurodegeneration, GCL thickening may indicate inflammation, with secondary edema, glial cell infiltration, and vascular changes. Both processes have been implicated in GWI. A prospective MRI study found significant reductions in brainstem, cerebellar, and thalamus volumes in 17 GWI veterans compared to 23 controls, aligning with a neurodegenerative process. On the other hand, neuroinflammation has also been described in GWI in the form of autoantibodies to neural and glial cell tissue, including calmodulin kinase II (CaMKII) and neurofilament triplet proteins (NFP), which are also found on retinal ganglion cells (RGC). Linking neurodegeneration and inflammation in GWI, one study found that increased serum concentrations of the inflammatory marker, soluble receptor II for tumor necrosis factor, was significantly associated with reduced hippocampal volume in GWI veterans. Thus, it is possible that individuals with diffuse inflammation on top of neurodegeneration may have RNFL thinning but GCL thickening while those with a more prominent neurodegeneration component have thinning in both layers. However, longitudinal studies are needed to evaluate our hypotheses.

In our final analysis, we explored whether specific OCT parameters could help discriminate between GWI and controls. We found that RNFL thickness, in conjunction with other parameters, predicted 80% of the variability in GWI risk. Similar regression analysis using minimum RNFL thickness and age predicted brain atrophy in patients with MS. Other OCT parameters were also predictive of a GWI diagnosis including decreased average
cup-to-disc (CD) ratio. This finding may be driven by mechanisms related to GWI, such as toxic or inflammatory changes, or may be due to an unrelated confounder, such as a higher frequency of individuals with physiologic cupping in the non-GWI group. Younger age also remained in the model as a predictor of GWI. This may simply reflect that older age may be an unexplained contributor to GWI risk. Nevertheless, our data suggest that OCT has the potential to detect GWI and perhaps monitor disease progression. This is needed as GWI is a disease significant with morbidity and no disease-modifying therapies. Methods are thus needed to detect GWI early, identify GWI sub-types, and monitor for disease progression. Similar approaches have been investigated in other neuroinflammatory diseases, such as MS. In one study, OCT detected MS in the early stages of disease35, leading to early treatment which improved disease severity and morbidity36.

Our findings must be considered in light of the study limitations which included a retrospective design in a defined study population with a fixed sample size. As such, assessment of eye diseases was not performed in a standard method by individual clinicians. Furthermore, we used both phone and clinic-based interviews to define GWI. However, we used one of the two questionnaires (Kansas criteria) recommended by the Institute of Medicine and the United States Department of Defense in both settings37. Balancing the limitations are the strengths of this study which include the only study to our knowledge to evaluate ocular manifestations and non-invasive ocular biomarkers of GWI. Additional studies are thus needed to independent cohorts to replicate our findings and examine change over time, as has been done for other neurodegenerative diseases38. In fact, our plan is to further explore and validate the predictive markers discussed in this manuscript in a novel population. Despite these limitations, our findings open the possibility of studying OCT as biomarkers of GWI, which is greatly needed as GWI is a disease with high morbidity but with no therapeutic interventions.

Data availability
The datasets generated during and/or analyzed during the current study are not publicly available due to lack of permission from Veterans Health Administration to share data.

Received: 15 May 2020; Accepted: 28 February 2021
Published online: 22 March 2021

References
1. Steele, L. Prevalence and patterns of Gulf War illness in Kansas veterans: Association of symptoms with characteristics of person, place, and time of military service. *Am. J. Epidemiol.* **152**, 992–1002 (2000).
2. Hubbard, N. A. *et al.* Central executive dysfunction and deferred prefrontal processing in veterans with Gulf War Illness. *Clin. Psychol. Sci.* **2**, 319–327. https://doi.org/10.1177/2167702613506580 (2014).
3. Cherry, R. *et al.* Health and exposures of United Kingdom Gulf war veterans. Part II: The relation of health to exposure. *Occup. Environ. Med.* **58**, 299–306. https://doi.org/10.1136/oem.58.5.299 (2001).
4. Dursa, E. K., Barth, S. K., Schneiderman, A. I. & Bossarte, R. M. Physical and mental health status of Gulf War and Gulf Era Veterans: results from a large population-based epidemiologic study. *J. Occup. Environ. Med.* **58**, 41–46. https://doi.org/10.1097/JOM.0000000000000273 (2016).
5. Chen, C. H. *Dry eye syndrome risks in patients with fibromyalgia: A national retrospective cohort study.* Medicine **95**, e2607. https://doi.org/10.1097/MD.0000000000002607 (2016).
6. Chen, C. S. *et al.* Dry eye syndrome and the subsequent risk of chronic fatigue syndrome-a prospective population-based study in Taiwan. *Oncotarget* **9**, 30694–30703. https://doi.org/10.18632/oncotarget.25544 (2018).
7. Huang-Link, Y. M., Fredrikson, M. & Link, H. Benign multiple sclerosis is associated with reduced thinning of the retinal nerve fiber and ganglion cell layers in non-optic-neuritis eyes. *J. Clin. Neurol.* **11**, 241–247. https://doi.org/10.3998/jcn.2015.11.3.241 (2015).
8. García-Martin, E. *et al.* Retina measurements for diagnosis of Parkinson disease. *Retina* **34**, 971–980. https://doi.org/10.1097/IAE.0000000000000282 (2014).
9. Coppola, G. *et al.* Optical coherence tomography in alzheimer’s disease: A meta-analysis. *PLoS ONE* **10**, e0134750. https://doi.org/10.1371/journal.pone.0134750 (2015).
10. Cheung, C. Y. *et al.* Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer’s disease. *J. Alzheimers Dis.* **45**, 45–56. https://doi.org/10.3233/JAD-141659 (2015).
11. Gonzalez-Lopez, I. J. *et al.* Comparative diagnostic accuracy of ganglion cell-inner plexiform and retinal nerve fiber layer thickness measures by Cirrus and Spectralis optical coherence tomography in relapsing-remitting multiple sclerosis. *Biomed. Res. Int.* **2014**, 128517. https://doi.org/10.1155/2014/128517 (2014).
12. Narayan, D. *et al.* Tracking changes over time in retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in multiple sclerosis. *Mult. Scler.* **20**, 1331–1341. https://doi.org/10.1177/1352458514523498 (2014).
13. Burkeholder, B. M. *et al.* Macular volumetric determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. *Arch. Neurol.* **66**, 1366–1372. https://doi.org/10.1001/archneur.2009.230 (2009).
14. Garcia-Martin, E. *et al.* Neuro-ophthalmologic evaluation, quality of life, and functional disability in patients with MS. *Neurology* **81**, 76–83. https://doi.org/10.1212/01.WNL.0000318299c9d9 (2013).
15. Saidha, S. *et al.* Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. *Mult. Scler.* **17**, 1449–1463. https://doi.org/10.1177/1352458511418650 (2011).
16. Haley, R. W., Kurt, T. L. & Hom, J. Is there a Gulf War Syndrome? Searching for syndromes by factor analysis of symptoms. *JAMA* **277**, 215–222 (1997).
17. Bewick, V., Cheek, L. & Ball, J. Statistics review 8: Qualitative data: tests of association. *Crit. Care* **8**, 46–53. https://doi.org/10.1186/cc2428 (2004).
18. Perneger, T. V. What’s wrong with Bonferroni adjustments. *BMJ* **316**, 1236–1238 (1998).
19. Bron, A. *et al.* TFOS DEWS II pathobiology report. *Ocul. Surf.* **15**, 438–510. https://doi.org/10.1016/j.jtos.2017.05.011 (2017).
20. Belmonte, C. *et al.* TFOS DEWS II pain and sensation report. *Ocul. Surf.* **15**, 404–437. https://doi.org/10.1016/j.jtos.2017.05.002 (2017).
21. Doust, J., Torbati, T., Black, K. L., Koronyo, Y. & Koronyo-Hamaoui, M. Optical coherence tomography in Alzheimer’s disease and other neurodegenerative diseases. *Front. Neurol.* **8**, 701. https://doi.org/10.3389/fneur.2017.00701 (2017).
22. Pitcher, T. L. et al. Reduced striatal volumes in Parkinson’s disease: A magnetic resonance imaging study. *Transl. Neurodegener.* **1**, 17 (2012).
23. Chao, L. Do Gulf War veterans with high levels of deployment-related exposures display symptoms suggestive of Parkinson’s disease? *Int. J. Occup. Med. Environ. Health* **32**, 503–526. https://doi.org/10.13075/ijomeh.1896.01346 (2019).
24. Henderson, A. P. et al. An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. *Brain* **131**, 277–287. https://doi.org/10.1093/brain/awm285 (2008).
25. Chrysou, A., Jansonius, N. M. & van Laar, T. Retinal layers in Parkinson’s disease: A meta-analysis of spectral-domain optical coherence tomography studies. *Parkinsonism Relat. Disord.* **64**, 40–49. https://doi.org/10.1016/j.parkreldis.2019.04.023 (2019).
26. Mead, B. & Tomarev, S. Evaluating retinal ganglion cell loss and dysfunction. *Exp. Eye Res.* **151**, 96–106. https://doi.org/10.1016/j.exer.2016.08.006 (2016).
27. Christova, P. et al. Subcortical brain atrophy in Gulf War Illness. *Exp. Brain Res.* **235**, 2777–2786. https://doi.org/10.1007/s00221-017-5010-8 (2017).
28. Abou-Donia, M. B. et al. Screening for novel central nervous system biomarkers in veterans with Gulf War Illness. *Neurotoxicol. Teratol.* **61**, 36–46. https://doi.org/10.1016/j.ntt.2017.03.002 (2017).
29. Cooper, N. G., Laabich, A., Fan, W. & Wang, X. The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells. *Prog. Brain Res.* **173**, 521–540. https://doi.org/10.1016/s0079-6123(08)01136-9 (2008).
30. Nixon, R. A., Paskevich, P. A., Sihaq, R. K. & Thayer, C. Y. Phosphorylation on carbonyl terminus domains of neurofilament proteins in retinal ganglion cell neurons in vivo: Influences on regional neurofilament accumulation, internurofilament spacing, and axon caliber. *J. Cell Biol.* **126**, 1031–1046. https://doi.org/10.1083/jcb.126.4.1031 (1994).
31. O’Donovan, A. et al. Altered inflammatory activity associated with reduced hippocampal volume and more severe posttraumatic stress symptoms in Gulf War veterans. *Psychoneuroendocrinology* **51**, 557–566. https://doi.org/10.1016/j.psyneuen.2014.11.010 (2015).
32. Sung, K. R. et al. Macular assessment using optical coherence tomography for glaucoma diagnosis. *Br. J. Ophthalmol.* **96**, 1452–1455. https://doi.org/10.1136/bjophthalmol-2012-301845 (2012).
33. Campbell, J. P. et al. Detailed vascular anatomy of the human retina by projection-resolved optical coherence tomography angiography. *Sci. Rep.* **7**, 42201. https://doi.org/10.1038/srep42201 (2017).
34. Gordon-Lipkin, E. et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. *Neurology* **69**, 1603–1609. https://doi.org/10.1212/01.wnl.0000293995.46586.ae (2007).
35. Balk, L. J. et al. Timing of retinal neuronal and axonal loss in MS: A longitudinal OCT study. *J. Neurool.* **263**, 1323–1331. https://doi.org/10.1070/S0041-0612(16)-09173-7 (2016).
36. Kavalunas, A. et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. *Mult. Scler.* **23**, 1233–1240. https://doi.org/10.1177/1352458516675039 (2017).
37. The Gulf War Illness Landscape. https://cdmrp.army.mil/gwirp/pdfs/GWIRP_Landscape_2020.pdf (2020).
38. Bebbehani, R., Adnan, H., Al-Hassan, A. A., Al-Salah, A. & Alrouhani, R. Predictors of retinal atrophy in multiple sclerosis: A longitudinal study using spectral domain optical coherence tomography with segmentation analysis. *Mult. Scler. Relat. Disorder.* **21**, 56–62. https://doi.org/10.1016/j.msard.2018.02.010 (2018).

**Author contributions**

All authors substantially contributed to this manuscript. Data collection: B.S.B., K.Z., and A.G. Data analysis: B.S.B., A.G., and R.G. Drafting manuscript: B.S.B., K.Z., A.G., and R.G. Critical revision of manuscript: B.S.B., K.Z., R.G., E.F., N.K. and A.G.

**Funding**

Supported by the Department of Defense Gulf War Illness Research Program (GWIRP) W81XWH-20-1-0579 (Dr. Galor) and Vision Research Program (VRP) W81XWH-20-1-0820 (Dr. Galor), Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences R&D (CSRD) I01 CX002015 (Dr. Galor) and Biomedical Laboratory R&D (BLRD) Service I01 BX004893 (Dr. Galor), National Eye Institute R01EY026174 (Dr. Galor) and R61EY032468 (Dr. Galor), NIH Center Core Grant P30EY014801 (institutional) and Research to Prevent Blindness Unrestricted Grant (institutional).

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-86061-0.

**Correspondence** and requests for materials should be addressed to A.G.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021